LENZ Therapeutics to Speak at Jefferies Global Healthcare Conference

SAN DIEGO, May 30, 2024 – LENZ Therapeutics, Inc. (Nasdaq: LENZ), a late-stage clinical biopharmaceutical company, had announced its participation in the Jefferies Global Healthcare Conference. Eef Schimmelpennink, the President and CEO of LENZ Therapeutics, delivered a presentation and engaged in one-on-one meetings during the event, which was scheduled for June 5-6, 2024, in New York City.

The live audio webcast of the CEO's presentation was accessible via the LENZ Therapeutics website under the Investors & Media section. Furthermore, a replay of the webcast was available on the company's website for 30 days post-event.

About LENZ Therapeutics:
LENZ Therapeutics is at the forefront of developing the first aceclidine-based eye drop designed to improve near vision for individuals suffering from presbyopia. Their leading product candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 has been thoroughly evaluated in the pivotal Phase 3 CLARITY study, aimed at treating presbyopia – a condition that affects approximately 1.8 billion people worldwide, including 128 million in the United States.

With a mission to provide an optimal pharmaceutical solution for presbyopia, LENZ Therapeutics is dedicated to enhancing near vision for “all eyes, all day.” The company is headquartered in San Diego, California.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!